Report – Page 2 – Alligator Bioscience

2024-05-06

Regulatory

Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update

Mitazalimab Phase 3 preparations underway following positive top-line results from OPTIMIZE-1 Phase 2 study in pancreatic cancer Positive in ...

2024-03-21

Regulatory

Lund, Sweden, March 21, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2023, as ...

2024-02-082024-02-14

Regulatory

Mitazalimab meets OPTIMIZE-1 Phase 2 primary endpoint, demonstrating 40.4% Overall Response Rate and median Overall Survival of 14.3 months ...

2023-10-26

Regulatory

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-04-25

Mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer completes enrolment following positive interim results; top-line data due Q1 2024 ...

2023-03-24

Regulatory

Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...

2023-02-10

Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...

2022-10-20

Patient enrolment for OPTIMIZE-1 Phase 2 study ahead of schedule with top-line data now brought forward to Q1 2024 and interim data on track ...